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Do clinical investigations predict long-term outcome?  40 
A follow-up of paediatric respiratory outpatients 41 
de Jong CCM, Pedersen ESL, Goutaki M, Trachsel M, Barben J, Kuehni CE 42 
 43 
Abstract (250/250) 44 
Introduction: The contribution of clinical investigations to prediction of long-term outcomes 45 
of children investigated for asthma is unclear. 46 
Aim: We performed a broad range of clinical tests and investigated whether they helped to 47 
predict long-term wheeze among children referred for evaluation of possible asthma. 48 
Methods: We studied children aged 6-16 years referred to two Swiss pulmonary outpatient 49 
clinics with a history of wheeze, dyspnoea, or cough in 2007. The initial assessment included 50 
spirometry, fractional exhaled nitric oxide, skin prick tests, and bronchial provocation tests 51 
(BPT) by exercise, methacholine, and mannitol. Respiratory symptoms were assessed with 52 
questionnaires at baseline and at follow-up seven years later. Associations between 53 
baseline factors and wheeze at follow-up were investigated by logistic regression. 54 
Results: At baseline, 111 children were examined in 2007. Seven years after baseline, 85 55 
(77%) completed the follow-up questionnaire, among whom 61 (72%) had wheeze at 56 
baseline, while at follow-up 39 (46%) reported wheeze. Adjusting for age and sex, the 57 
following characteristics predicted wheeze at adolescence: wheeze triggered by pets (odds 58 
ratio 4.2, 95% CI 1.2-14.8), pollen (2.8, 1.1-7.0), and exercise (3.1, 1.2-8.0). Of the clinical 59 
tests, only a positive exercise test (3.2, 1.1-9.7) predicted wheeze at adolescence. 60 
Conclusion: Reported exercise-induced wheeze and wheeze triggered by pets or pollen 61 
were important predictors of wheeze persistence into adolescence. None of the clinical tests 62 
predicted wheeze more strongly than reported symptoms. Clinical tests might be important 63 
for asthma diagnosis but medical history is more helpful in predicting prognosis in children 64 
referred for asthma. 65 
66 
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Introduction 67 
Asthma is the most prevalent chronic respiratory disease in childhood and adolescence, 68 
which leads to many health care visits1-3. Its key symptoms are wheeze, cough, and difficulty 69 
breathing, but symptoms vary substantially between individuals and across ages1,2. Some 70 
children who present with asthma symptoms continue to have problems later in life, while 71 
others do not. Better knowledge of their individual prognoses might affect their follow-up and 72 
answer questions of parents in the clinics4-6. Assessing prognosis of asthma symptoms from 73 
school age into adulthood and identifying children at high-risk of symptom persistence is 74 
challenging4.  75 
Studies investigating prognosis of asthma or wheeze in school-aged children are conducted 76 
with either clinical asthma cohorts or symptomatic children of a population-based cohort7. 77 
Studies in clinical asthma cohorts have found that lower FEV1, asthma severity, sensitisation 78 
to indoor allergens, eczema, hay fever, skin test reactivity, and bronchial hyper-79 
responsiveness were associated with asthma persistence8-10. Studies in population-based 80 
cohorts have found that wheeze persistence was predicted by frequent attacks of wheeze, 81 
female sex, sensitization to furred animals or house dust mites, rhinitis, and bronchial hyper-82 
responsiveness11-16.  83 
For clinical practice, two knowledge gaps remain. First, few studies have examined the 84 
prediction of long-term prognosis, but none have done this for school-aged children seen in 85 
outpatient clinics for possible asthma. Second, many tests are performed in clinics to 86 
diagnose these children, but it is unclear whether these tests predict prognosis more 87 
accurately than reported symptoms alone. We determined whether clinical tests in addition 88 
to reported symptoms help predict wheeze in adolescence in school-aged children referred 89 
for possible asthma. 90 
 91 
 92 
 93 
 94 
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Methods 95 
Study population and study design 96 
Of the 124 children invited, 111 were recruited from the respiratory outpatient clinics of two 97 
paediatric hospitals in Switzerland, 84 from St. Gallen and 27 from Basel, who were eligible 98 
if they had been referred for evaluation of current wheeze, dyspnoea, or cough. Children 99 
with a known chronic respiratory disease such as cystic fibrosis or primary ciliary dyskinesia, 100 
or a respiratory tract infection during four weeks prior to the visit were excluded. At baseline 101 
in 2007-2008, parents completed a questionnaire and children underwent a set of 102 
standardised clinical tests during two different visits within one week as part of the study 103 
protocol17,18. At follow-up, seven years after baseline, in 2014 to 2015, we sent a 104 
questionnaire to the 12-23 year-old adolescents or young adults (from now on referred to as 105 
adolescents) (E-figure 1). 106 
Ethical approval was obtained from the local Ethics committee and all parents gave informed 107 
consent during the first visit at baseline and by sending back the questionnaire at follow-up 108 
(EKSG 07/001).  109 
 110 
Baseline assessment 111 
The parental questionnaire included ISAAC key questions19 plus additional questions on 112 
type and triggers of respiratory symptoms, atopic symptoms, previous treatments and 113 
environmental exposures (Supplementary questionnaire 1 (German, original) and 2 (English, 114 
translation)). The study physician reported clinical test results, final diagnosis, and 115 
prescribed medication in a uniform way. Physicians diagnosed the children after all clinical 116 
tests were done, taking into consideration medical history, clinical examination, and all test 117 
results. Vocal cord dysfunction was diagnosed based on medical history, physical 118 
examination and normal expiratory curves in spirometry. 119 
The baseline assessment consisted of two visits. At the initial baseline visit, children 120 
performed spirometry, fractional exhaled nitric oxide (FeNO) measurement, a skin prick test 121 
(SPT), bronchial provocation test (BPT) by exercise and, by methacholine. At the second 122 
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baseline visit, children did a BPT by mannitol. All clinical tests were performed according to 123 
published guidelines20-24. A detailed description of the test procedures has been published 124 
elsewhere 17,18,25 and is included in the online supplementary material (E-text). Lung function 125 
measurements were compared to reference values from Zapletal et al26. We considered the 126 
exercise test as positive in the event of a ≥15% decrease in the FEV1 after the exercise 127 
challenge test, and the methacholine test as positive when the minimal dose causing a 128 
≥20% decrease of FEV1 was <1mg (the provocation dose, PD 20). The mannitol dry powder 129 
challenge test was considered as positive when a 15% fall in FEV1 was measured before a 130 
cumulative dose of 635 mg was reached, or when a 10% fall in FEV1 between two doses 131 
was reached. FeNO was measured using the portable NIOX MINO® device, and was 132 
considered as positive when FeNO was higher than 26ppb18. We performed skin prick tests 133 
for birch, grass, mugwort, alternaria, cat, house dust mites (D. pteronysinus), and positive 134 
and negative controls18. These allergens cover 95% of inhaled allergens in Switzerland27. 135 
The test was considered to be positive if any mean wheal diameter was ≥3mm. 136 
 137 
Assessment at follow-up 138 
The follow-up questionnaire was very similar to the baseline questionnaire, but the questions 139 
were addressed directly to the adolescents instead of their parents (supplementary 140 
questionnaire 3 (German, original) and 4 (English, translation)). 141 
 142 
Definitions of wheeze and frequent wheeze 143 
We assessed wheeze at follow-up with the question, "Have you had a whistling sound in the 144 
chest in the last 12 months?" If a child had had more than three attacks of wheeze in the last 145 
12 months, we considered the child to have had frequent wheeze. 146 
 147 
Statistical analysis 148 
We compared the participants with information at baseline and follow-up to those without 149 
follow-up information to test for selection bias, using chi-square test. The participants with 150 
6 
 
information at baseline and follow-up were included in the analysis.  151 
We investigated the association between exercise-induced wheeze and a positive exercise 152 
test at baseline using the Fisher’s exact test, and the Mann-Whitney-U test when looking at 153 
the association of reported exercise-induced wheeze and the fall of FEV1% predicted during 154 
the exercise test.  155 
We investigated the association between symptoms (table 1) and clinical test results (table 156 
2) at baseline with any wheeze and frequent wheeze at follow-up using logistic regression, 157 
adjusting for sex and age. For comparison, we repeated the analysis including only children 158 
diagnosed with asthma (N=62). We did not consider interactions or a multivariable model 159 
because of the sample size. We used STATA software (version 14; College Station, Texas) 160 
to analyse the data. 161 
 162 
Results 163 
Characteristics of the study population at baseline and at follow-up 164 
Eighty-five (77%) of the 111 children who participated in the baseline study completed the 165 
follow-up questionnaire. The median age was 12 years at baseline (range 6-16) and 18 at 166 
follow-up (12-23); 60% (51/85) were male. Wheeze was reported by 61 (72%) at baseline, 167 
and 7 reported cough without wheeze, 12 (14%) reported exercise-related breathing 168 
problems and 5 (6%) reported allergic rhinitis. Among those with wheeze, 27 (44%) had 169 
more than three attacks during 12 months prior to the baseline visit (Table 1). Symptoms at 170 
baseline were very similar in children who did not take part in the follow-up (E-table 1 online 171 
supplementary material). Asthma medication was prescribed at the baseline visit for 71 172 
(85%) children, of whom 47 (55%) received inhaled short-acting β2-agonists (SABA) alone, 173 
6 received SABA and inhaled corticosteroids (ICS), and 18 received long-acting β2-agonists 174 
(LABA) and ICS. At follow-up, 39 (46%) participants reported wheeze of whom 30 had more 175 
than 3 attacks during the last year. At follow-up, 44 adolescents (52%) reported using 176 
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inhalers, including 21 using SABA alone, 2 using SABA and ICS, and 21 using LABA and 177 
ICS (Table 1). 178 
 179 
Table 2 shows the clinical test results and diagnoses at baseline. All tests were completed in 180 
at least 90% of the children. The main reason for not completing a BPT was exhaustion17,18. 181 
For the 78 children who completed the BPT by methacholine at baseline, the test was 182 
positive in 76% and the median provocation dose was 0.14mg. Eighty-two completed the 183 
BPT by mannitol, of whom 28% tested positive. The median provocation dose was 635 mg. 184 
Of the 76 children who completed the BPT by exercise, the median fall of FEV1 was 8% 185 
predicted. The test was positive (≥15% decrease in the FEV1) in 18 (24%) children.  SPT 186 
was positive in 33 (39%) children and FeNO was positive in 35 (41%). Doctors diagnosed 62 187 
(73%) children with asthma or episodic viral wheeze. The other children were mostly 188 
diagnosed with cough not due to asthma or vocal cord dysfunction. 189 
At baseline, self-reported exercise-induced wheeze was associated with a positive exercise 190 
test (p=0.022, E-table 2). 191 
 192 
Baseline factors associated with wheeze and frequent wheeze at follow-up 193 
Four respiratory symptoms and one clinical test at baseline were associated with any 194 
wheeze at follow-up. Of the reported symptoms, frequent wheeze (>3 attacks) (OR 2.86, 195 
95% CI 1.10-7.43), exercise-induced wheeze (3.07, 1.19-7.96), wheeze triggered by pets 196 
(4.22, 1.21-14.76), and wheeze triggered by pollen (2.78, 1.11-6.98) were associated with 197 
wheeze at follow-up. For the clinical tests, only a positive exercise test was significantly 198 
associated with wheeze seven years later (3.20, 1.05-9.70). Results remained very similar 199 
after adjusting for age and sex (Table 3). When we repeated the analysis for children 200 
diagnosed with asthma (N=62), we found mostly comparable results (E-table 3). However, 201 
associations tended to be less strong (lower odds ratios) in particular for exercise induced 202 
wheeze (1.79, 0.58-5.48) and positive exercise test (2.00, 0.63-6.39)  203 
 204 
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Two respiratory symptoms were associated with frequent wheeze at follow-up. These were 205 
exercise-induced wheeze (OR 3.05, 95% CI 1.07-8.67) and wheeze triggered by pets (3.79, 206 
1.15-12.48; E-table 4). None of the clinical test results were associated with frequent wheeze 207 
at follow-up. 208 
 209 
Discussion 210 
Among school-aged children referred to a respiratory outpatient clinic for evaluation of 211 
wheeze, cough, or dyspnoea, 46% reported wheeze seven years later. Reported exercise-212 
induced wheeze and wheeze triggered by pets or pollen at baseline predicted wheeze at 213 
follow-up. Of the clinical tests, only a positive exercise challenge test predicted wheeze at 214 
follow-up, but no more strongly than reported exercise-induced wheeze. When we repeated 215 
the analysis based on children with asthma only, associations were weaker, probably 216 
because the same characteristics that predicted persistence (exercise induced wheeze, 217 
positive exercise test) had already been used by the clinicians to decide on a diagnosis of 218 
asthma. 219 
A few studies have examined the prediction of prognosis by clinical testing, but ours is the 220 
only study to have done this for so many clinical tests in school-aged children referred to a 221 
respiratory outpatient clinic. We did not find an association between FEV1 or bronchial 222 
provocation test by methacholine at baseline and wheeze seven years later; previous 223 
studies have reported contradictory findings. Both the CAMP cohort of 909 children aged 5-224 
12 years with diagnosed asthma and another Dutch clinical cohort study of 5-14 year-old 225 
children diagnosed with asthma found that asthma persistence at ages 15-20 and 32-42, 226 
respectively, was associated with decreased FEV1 at school-age8,9. In contrast, the 227 
population-based Tasmanian cohort did not find an association between FEV1 at age 7 and 228 
wheeze persistence at age 29-3215. The CAMP study also found that a lower methacholine 229 
provocation concentration was associated with asthma persistence from age 5-12 until age 230 
15-209. In contrast, the population based Dunedin cohort of 613 children reporting wheeze at 231 
age 9 and a Norwegian cohort of 62 children reporting asthma at age 10, found that 232 
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bronchial provocation test by methacholine was not associated with persistence at age 26 233 
and 16 respectively, which is in line with our findings12,28. The Norwegian cohort did not find 234 
bronchial provocation test by exercise to be associated with asthma persistence from age 10 235 
to age 16, which is in contrast to the association we found28. This heterogeneity between 236 
studies could be because children with wheeze from population-based cohorts might have 237 
milder disease than those in clinical studies. FeNO was not associated with wheeze 238 
persistence in children aged 6-16 years old suspected for asthma in our study. In contrast, 239 
FeNO was reported to predict asthma in pre-school children with wheeze29-32. To our 240 
knowledge, no studies assess the predictive value of FeNO on wheeze persistence at school 241 
age. Available publications assessed the predictive value of FeNO on asthma control, 242 
relapse or exacerbations in asthmatic children, but with a short follow-up33-36. . 243 
Our observation that frequent attacks of wheeze at school age predicted wheeze persistence 244 
seven years later is in line with findings from the Melbourne and Tasmanian cohorts10,11. In 245 
contrast to their findings, we found no significant association between either eczema or hay 246 
fever at baseline and wheeze persistence. This could be because those cohorts used 247 
different outcomes—severe wheeze and atopic asthma, respectively—or simply because we 248 
had low numbers and limited power. 249 
A possible limitation of our study was that the bronchial provocation tests were done within a 250 
short period of time. This could have influenced the methacholine test result, which was 251 
performed after the exercise test on the same day and was positive in 76% of the children. 252 
Most likely the bronchial provocation test by mannitol was not influenced by the short time 253 
interval. We assured an appropriate interval of at least 24 hours without a change in 254 
respiratory health or medication in this time interval. A second limitation was the small 255 
sample size, which limited statistical power and did not allow us to perform a multivariable 256 
analysis including all symptoms and test results simultaneously. Adolescents might have 257 
underreported respiratory symptoms, which might have led to an underestimation of the 258 
proportion of adolescents with wheeze. However, since this underreporting is not likely to be 259 
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associated with symptoms or positive test results at baseline, this should not have influenced 260 
the results relating to risk factors. 261 
The main strength of our study is its clinical design, which reflects the typical mix of patients 262 
in a paediatric outpatient clinic. All children were first-time referrals to the paediatric 263 
respiratory clinic for evaluation of possible asthma. Therefore, the study population is 264 
representative of daily clinical work, in contrast to many clinical studies that selectively 265 
include well-defined moderate to severe asthmatics and leave out patients with unclear 266 
degrees of airway reactivity. Our study also profited from a very detailed baseline 267 
examination. Children in the study had an extensive array of examinations for lung function, 268 
BPT and allergy, which allowed us to assess the contribution of clinical tests in predicting 269 
long-term wheeze in addition to reported symptoms among those referred for evaluation of 270 
possible asthma.  271 
 272 
Conclusion 273 
This study is an initial step towards finding out whether clinical tests can predict wheeze later 274 
in life. Though clinical tests might be important for asthma diagnosis, our results suggest that 275 
they do not strongly predict prognosis of wheeze. In contrast, our data underline the 276 
importance of a detailed history, as school-age children reporting exercise-related wheeze 277 
and wheeze triggered by allergens were at higher risk and thus might profit from more 278 
frequent follow-up. 279 
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